AAPS open

· 1 paper in corpus

lab-animal 2023

Extraction of niclosamide from commercial approved tablets into aqueous buffered solution creates potentially approvable oral and nasal sprays against COVID-19 and other respiratory infections

doi:10.1186/s41120-023-00072-x ·PMID:37073302

MOTIVATION: The low solubility, weak acid drug, niclosamide is a host cell modulator with broad-spectrum anti-viral cell-activity against many viruses, including stopping the SARS-CoV-2 virus from infecting cells in cell culture. As a resul…